🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Immune Modulation by Exosomes in COVID-19

Recruitingn/aAges 18 Years - 90 YearsAllUniversity of Ulm
NCT05191381 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Critically ill COVID-19 patients with lung dysfunction * COVID-19 WHO severity degree \>= 4, ARDS (WHO Definition 13 March 2020) * Body weight \> 50 kg * Informed consent Exclusion Criteria: * Pregnant or breast feeding women
💊

What it tests

  • Application of exosomes in a whole blood assay
📍

Where

1 site
Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine
Ulm, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy